Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert J. Dempsey
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 0.04
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.30
Financials
Net Income
$-6.36MEBITDA
$-6.41MFree Cash Flow
$-4.41MEPS (diluted)
$-0.17Shares Outstanding (diluted)
37.39M+772.9%Operating Expenses
$6.41MCash & Debt
$20.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-8.95M | $-0.24 |
| 2025 | $0.00 | $-4.71M | $-0.12 |
| 2024 | $0.00 | $-16.83M | $-0.00 |
| 2023 | $0.00 | $-13.27M | $-0.60 |
| 2022 | $0.00 | $-5.43M | $-0.36 |
| 2021 | $0.00 | $-3.35M | $-0.32 |
| 2020 | $0.00 | $-1.54M | $-0.17 |
| 2019 | $0.00 | $-4.89M | $-0.62 |
| 2018 | $0.00 | $-28.30M | $-4.80 |
| 2017 | $0.00 | $-243.0K | $-0.04 |
| 2016 | $0.00 | $-820.0K | $-0.17 |
| 2015 | $0.00 | $-8.26M | $-1.32 |
| 2014 | $0.00 | $-13.95M | $-0.05 |
| 2013 | $0.00 | $-4.84M | $-1.09 |
Valuation
OKYOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Positive
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).
View source ↗ - Newsglobenewswire.com·7d ago·Positive
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
View source ↗ - Newsglobenewswire.com·27d ago·Positive
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.
View source ↗
Earnings
Wed, Dec 2(in 8 weeks)
Consensus estimate $-0.06 per share
Typical surprise +19.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jul 20$-0.15 vs $-0.08miss
- Fri, Jan 30$-0.01 vs $-0.07beat
- Fri, Jul 18$-0.04 vs $-0.05beat
Estimates and results for OKYO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OKYO officers and directors.
- Bought
- $995k
- Sold
- —
13 trades
0 trades
- Patil Rajkumar V.bought
- Dempsey Robert Johnbought
- Brancaccio John Pbought
- Jacob Gary Sbought
- Cerrone Gabriele Mbought
- Mantelli Flaviobought
- Cerrone Gabriele Mbought
- Brancaccio John Pbought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OKYO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.